Research progress in the diagnosis and treatment of urothelial carcinoma at the 2022 ASCO-GU
10.3760/cma.j.cn112330-20220408-00180
- VernacularTitle:2022 ASCO-GU尿路上皮癌精粹解析
- Author:
Wang HE
1
;
Hai HUANG
Author Information
1. 中山大学孙逸仙纪念医院泌尿外科，广州 510289
- Keywords:
Urologic neoplasms;
Urothelial carcinoma;
Bladder cancer;
Upper urinary tract urothelial carcinoma;
American society of clinical oncology
- From:
Chinese Journal of Urology
2022;43(4):245-248
- CountryChina
- Language:Chinese
-
Abstract:
In 2022, ASCO genitourinary cancer symposium reported the latest progress in the diagnosis and treatment of urothelial carcinoma. Perioperative treatment progress include prediction of the effect of neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC) and upper urinary tract epithelial carcinoma (UTUC). The matched cohort study of bladder-sparing treatment showed that the effect of trimodality therapy (TMT) and radical cystectomy was equivalent in oncologic outcome. Immunotherapy showed promising effects in the circumstance of advanced urothelial carcinoma, neoadjuvant therapy and non muscle invasive bladder cancer (NMIBC) treatment. Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors and antibody coupled drugs (ADC) show antitumor activity in the treatment of advanced urothelial carcinoma. The meeting also reported a series of progress in biomarkers related to the prediction of curative effect of urothelial carcinoma.
